Pfizer releases vaccine data for 5-11 age group, affirms safety and efficacy

Pfizer today released the first data evaluating a COVID-19 vaccine’s safety and effectiveness for children between the ages of 5 and 11. The data, culled from a phase 2/3 trial, indicates that two, 10-microgram doses of Pfizer’s mRNA vaccine, administered 21 days apart, resulted in a strong immune response against SARS-CoV-2. Pfizer said the data would be included in a “near-term” application to the Food and Drug Administration for emergency use authorization in the 5-11 age group. The drug maker also indicated that it would soon have sufficient trial data for children under 5 for submission to FDA.